INFLAMMA-K (DICLOFENAC SODIUM/METHYL SALICYLATE/MENTHOL/CAMPHOR)

Contraindicated



• None

Severe



• None

Contraindicated



• Aspirin exacerbated respiratory disease
• Drug-induced hepatitis
• Gastrointestinal perforation
• Hepatic failure
• Post-operative from CABG surgery
• Pregnancy
• Severe hepatic disease

Severe



• Abnormal hepatic function tests
• Acute myocardial infarction
• Alcoholism
• Burns
• Cerebrovascular accident
• Chronic heart failure
• Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
• Chronic kidney disease stage 5 (failure) GFr<15 ml/min
• Debilitation
• Disease of liver
• Duodenal ulcer
• Gastrointestinal hemorrhage
• Gastrointestinal ulcer
• Hypertension
• Increased cardiovascular event risk
• Increased risk of bleeding
• Peptic ulcer
• Skin ulcer
• Systemic mastocytosis
• Tobacco smoker

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

Diclofenac (Select Routes)

Safety and efficacy in pediatrics have not been established.

Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.

• 1 Day – 18 Years
• Safety and efficacy in pediatrics have not been established.
• 1 Day – 13 Years
• Safety and efficacy in pediatrics have not been established.

Salicylates (Topical)

Safety and efficacy in pediatrics have not been established.

Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.

• 1 Day – 18 Years
• Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
• 1 Day – 13 Years
• Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.